{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:16:55Z","timestamp":1790947015968,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Insmed Incorporated"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40262-022-01147-w","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T12:02:54Z","timestamp":1660737774000},"page":"1457-1469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacokinetic\/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5514-7868","authenticated-orcid":false,"given":"James D.","family":"Chalmers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Usansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Teper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Mange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"issue":"1","key":"1147_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-018-0042-3","volume":"4","author":"JD Chalmers","year":"2018","unstructured":"Chalmers JD, Chang AB, Chotirmall SH, Dhar R, McShane PJ. Bronchiectasis. Nat Rev Dis Primers. 2018;4(1):45.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"1147_CR2","doi-asserted-by":"publisher","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"E Polverino","year":"2017","unstructured":"Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.","journal-title":"Eur Respir J"},{"issue":"1018","key":"1147_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/pgmj.2009.091041","volume":"86","author":"P Goeminne","year":"2010","unstructured":"Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J. 2010;86(1018):493\u2013501.","journal-title":"Postgrad Med J"},{"issue":"8","key":"1147_CR4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.4187\/respcare.04004","volume":"60","author":"WJ Guan","year":"2015","unstructured":"Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, et al. Inflammatory responses, spirometry, and quality of life in subjects with bronchiectasis exacerbations. Respir Care. 2015;60(8):1180\u20139.","journal-title":"Respir Care"},{"issue":"4","key":"1147_CR5","doi-asserted-by":"publisher","first-page":"1902355","DOI":"10.1183\/13993003.02355-2019","volume":"55","author":"M Hagner","year":"2020","unstructured":"Hagner M, Frey DL, Guerra M, Dittrich AS, Halls VS, Wege S, et al. New method for rapid and dynamic quantification of elastase activity on sputum neutrophils from patients with cystic fibrosis using flow cytometry. Eur Respir J. 2020;55(4):1902355.","journal-title":"Eur Respir J"},{"key":"1147_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-3-319-22711-5_5","volume-title":"The serpin family: proteins with multiple functions in health and disease","author":"C Benarafa","year":"2015","unstructured":"Benarafa C. Regulation of neutrophil serine proteases by intracellular serpins. In: Geiger M, Wahlm\u00e8uller F, Furtm\u00e8uller M, editors. The serpin family: proteins with multiple functions in health and disease. Cham: Springer; 2015. p. 59\u201376."},{"issue":"1","key":"1147_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1165\/rcmb.2011-0380OC","volume":"47","author":"AV Dubois","year":"2012","unstructured":"Dubois AV, Gauthier A, Brea D, Varaigne F, Diot P, Gauthier F, et al. Influence of DNA on the activities and inhibition of neutrophil serine proteases in cystic fibrosis sputum. Am J Respir Cell Mol Biol. 2012;47(1):80\u20136.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"9","key":"1147_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/thoraxjnl-2018-212895","volume":"74","author":"O Sibila","year":"2019","unstructured":"Sibila O, Perea L, Canto E, Shoemark A, Cassidy D, Smith AH, et al. Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. Thorax. 2019;74(9):835\u201342.","journal-title":"Thorax"},{"issue":"10150","key":"1147_CR9","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","volume":"392","author":"PA Flume","year":"2018","unstructured":"Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018;392(10150):880\u201390.","journal-title":"Lancet"},{"issue":"6","key":"1147_CR10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/cpt.1053","volume":"104","author":"R Palmer","year":"2018","unstructured":"Palmer R, Maenpaa J, Jauhiainen A, Larsson B, Mo J, Russell M, et al. Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects. Clin Pharmacol Ther. 2018;104(6):1155\u201364.","journal-title":"Clin Pharmacol Ther"},{"issue":"22","key":"1147_CR11","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","volume":"383","author":"JD Chalmers","year":"2020","unstructured":"Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, et al. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020;383(22):2127\u201337.","journal-title":"N Engl J Med"},{"key":"1147_CR12","doi-asserted-by":"crossref","unstructured":"Usansky H, et al. Safety, tolerability, and pharmacokinetic evaluation of single and multiple doses of the dipeptidyl peptidase 1 (DPP1) inhibitor brensocatib in healthy Japanese and White adults. In: Poster presented at virtual ATS 2021 conference.","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A3938"},{"key":"1147_CR13","doi-asserted-by":"crossref","unstructured":"Usansky H, et al. Effects of food intake on the pharmacokinetics, safety, and tolerability of a single dose of the dipeptidyl peptidase 1 (DPP1) inhibitor brensocatib in healthy Japanese and White adults. In: Poster presented at virtual ATS 2021 conference.","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A3878"},{"issue":"1","key":"1147_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"issue":"6","key":"1147_CR15","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19(6):716\u201323.","journal-title":"IEEE Trans Autom Control"},{"issue":"2","key":"1147_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90(2):154\u201366.","journal-title":"Comput Methods Programs Biomed"},{"key":"1147_CR17","volume-title":"Introduction to linear regression analysis","author":"DC Montgomery","year":"2012","unstructured":"Montgomery DC, Peck EA, Vining GG. Introduction to linear regression analysis. 5th ed. New York: Wiley; 2012.","edition":"5"},{"issue":"6","key":"1147_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","volume":"43","author":"AG Dosne","year":"2016","unstructured":"Dosne AG, Bergstrand M, Harling K, Karlsson MO. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. J Pharmacokinet Pharmacodyn. 2016;43(6):583\u201396.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"1147_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","volume":"44","author":"AG Dosne","year":"2017","unstructured":"Dosne AG, Bergstrand M, Karlsson MO. An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn. 2017;44(6):509\u201320.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"1147_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"6","key":"1147_CR21","doi-asserted-by":"publisher","first-page":"1700051","DOI":"10.1183\/13993003.00051-2017","volume":"49","author":"AT Hill","year":"2017","unstructured":"Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017;49(6):1700051.","journal-title":"Eur Respir J"},{"issue":"7","key":"1147_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","volume":"186","author":"JD Chalmers","year":"2012","unstructured":"Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657\u201365.","journal-title":"Am J Respir Crit Care Med"},{"key":"1147_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"1147_CR24","doi-asserted-by":"publisher","first-page":"2000769","DOI":"10.1183\/13993003.00769-2020","volume":"56","author":"M Oriano","year":"2020","unstructured":"Oriano M, Gramegna A, Terranova L, Sotgiu G, Sulaiman I, Ruggiero L, et al. Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis. Eur Respir J. 2020;56(4):2000769.","journal-title":"Eur Respir J"},{"issue":"10","key":"1147_CR25","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1164\/rccm.201605-1027OC","volume":"195","author":"JD Chalmers","year":"2017","unstructured":"Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med. 2017;195(10):1384\u201393.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1147_CR26","doi-asserted-by":"publisher","first-page":"1900303","DOI":"10.1183\/13993003.00303-2019","volume":"53","author":"A Shoemark","year":"2019","unstructured":"Shoemark A, Cant E, Carreto L, Smith A, Oriano M, Keir HR, et al. A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation. Eur Respir J. 2019;53(6):1900303.","journal-title":"Eur Respir J"},{"issue":"1","key":"1147_CR27","doi-asserted-by":"publisher","first-page":"00252-2018","DOI":"10.1183\/23120541.00252-2018","volume":"5","author":"HR Keir","year":"2019","unstructured":"Keir HR, Fong CJ, Crichton ML, Barth P, Chevalier E, Brady G, et al. Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition. ERJ Open Res. 2019;5(1):00252\u20132018.","journal-title":"ERJ Open Res"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01147-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01147-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01147-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T02:38:26Z","timestamp":1665542306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01147-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1147"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01147-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"26 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The phase I study, phase II WILLOW study, and PK\/PD analysis presented in this publication were funded by Insmed Incorporated, Bridgewater, NJ, USA. The Open Access fee for the published article also was supported by Insmed Incorporated.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Institute for Clinical Pharmacodynamics\u00a0(ICPD), Inc. received funding from Insmed Incorporated to conduct the analyses and provide general consulting to Insmed Incorporated. Helen Usansky, Carlos Fernandez, Ariel Teper, Jun Zou, and Kevin C. Mange are employees of and shareholders in Insmed Incorporated. Christopher M. Rubino is an employee of ICPD, Inc. James D. Chalmers has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Zambon, and Insmed Incorporated; a grant from Gilead; and personal fees from Novartis and Chiesi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Individual anonymized participant data will not be made available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Both the phase I and WILLOW studies were performed in accordance with the ethical principles of the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Council for Harmonisation, and applicable regulatory requirements.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants provided written informed consent prior to any study procedures.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved and provided consent for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors contributed to study conception, data visualization, and the review and editing of the manuscript. JDC conducted research investigations. HU and CMR curated and analyzed data, conducted research investigations, developed methods, administered projects, supplied resources, developed and programmed software, supervised research activities, validated experiments, and wrote the original draft of the manuscript. AT and CF analyzed data, developed methods, and administered projects. JZ analyzed data, developed methods, developed and programmed software, and validated experiments. KCM analyzed data, developed methods, and supervised research activities.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}